SUTRO BIOPHARMA, INC. (STRO) › Cash & EquivalentsSUTRO BIOPHARMA, INC. (STRO) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2016: $11.59M2017: $22.02M2018: $125.30M2019: $4.96M2020: $206.15M2021: $30.41M2022: $47.25M2023: $69.27M2024: $190.30M2025: $58.13M$58.13M2016Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$58.13M-69.5%2024$190.30M+174.7%2023$69.27M+46.6%2022$47.25M+55.4%2021$30.41M-85.2%2020$206.15M+4056.3%2019$4.96M-96.0%2018$125.30M+469.0%2017$22.02M+89.9%2016$11.59M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share